Dengue vaccines

Vaccines

Volumn , Issue , 2008, Pages 1155-1161

  Halstead, Scott B ^a   Vaughn, David W ^b  

^a Pediatric Dengue Vaccines Initiative   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 45849094632     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3611-1.50047-7     Document Type: Chapter

References (121)

1. SB Halstead (1997) Epidemiology of dengue and dengue hemorrhagic fever. DJ Gubler, G Kuno (Eds) Dengue and dengue hemorrhagic fever New York: CAB International 23-44.
2. MI Meltzer, JG Rigau-Perez, GG Clark, et al. (1998) Using disability-adjusted life years to assess the economic impact of dengue in Puerto Rico: 1984–1994. Am J Trop Med Hyg 59(2), 265-271.
3. DJ Gubler and M Meltzer (1999) Impact of dengue/dengue hemorrhagic fever on the developing world. Adv Virus Research 53 35-70.
4. V Sung, GV Brown and J Torresi (2003) Dengue Fever in travelers returning from southeast Asia. J Travel Med 10(4), 208-213.
5. AL Rothman and FA Ennis (1999) Immunopathogenesis of Dengue hemorrhagic fever. Virology 257(1), 1-6.
6. SB Halstead, S Nimmannitya and SN Cohen (1970) Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J Biol Med 42 311-328.
7. N Sangkawibha, S Rojanasuphot, S Ahandrik, et al. (1984) Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am J Epidemiol 120 653-669.
8. SB Halstead (1988) Pathogenesis of dengue: challenges to molecular biology. Science 239 476-481.
9. DW Vaughn, S Green, S Kalayanarooj, et al. (2000) Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 181(1), 2-9.
10. SB Halstead and NJ Marchette (2003) Biologic properties of dengue viruses following serial passage in primary dog kidney cells: studies at the University of Hawaii. Am J Trop Med Hyg 69(6 Suppl), 5-11.
11. RV Gibbons and DW Vaughn (2002) Dengue: an escalating problem. BMJ 324(7353), 1563-1566.
12. DJ Gubler (2002) Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol 10(2), 100-103.
13. SB Halstead (1974) Etiologies of the experimental dengues of Siler and Simmons. Am J Trop Med Hyg 23(5), 974-982.
14. AB Sabin (1952) Research on dengue during World War II. Am J Trop Med Hyg 1 30-50.
15. W Sun, A Nisalak, M Gettayacamin, et al. (2006) Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination. J Infect Dis 193(12), 1658-1665.
16. SB Halstead, S Nimmannitya, C Yamarat and PK Russell (1967) Hemorrhagic fever in Thailand; recent knowledge regarding etiology. Jpn J Med Sci Biol 20 96-103.
17. MG Guzman, G Kouri, L Valdes, et al. (2000) Epidemiologic studies on dengue in Santiago de Cuba, 1997. Am J Epidemiol 152(9), 793-799.
18. JS Simmons, JH John St and FHK Reynolds (1931) Experimental studies of dengue. The Philippine Journal of Science 44 1-252.
19. G Blanc and J Caminopetros (1930) Experimental Research in Dengue. Annuals of the Pasteur Institute 44(4), 367-436.
20. AB Sabin and RW Schlesinger (1945) Production of immunity to dengue with virus modified by propagation in mice. Science 101 640-642.
21. S Hotta (1952) Experimental Studies in Dengue I. Isolation, Identification and Modification of the Virus. J Infect Dis 90(1), 1-9.
22. RW Schlesinger, I Gordon, JW Frankel, et al. (1956) Clinical and serologic response of man to immunization with attnuated dengue and yellow fever viruses. J Immunol 77(5), 352-364.
23. CL Wisseman Jr, BH Sweet, EC Rosenzweig and OR Eylar (1963) Attenuated Living Type 1 Dengue Vaccines. Am J Trop Med Hyg 12 620-623.
24. TP Monath (2005) Yellow fever vaccine. Expert Rev Vaccines 4(4), 553-574.
25. H Ohrr, JB Tandan, YM Sohn, et al. (2005) Effect of single dose of SA 14-14-2 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case-control study. Lancet 366(9494), 1375-1378.
26. SB Halstead and NE Palumbo (1973) Studies on the immunization of monkeys against dengue: II. Protection following inoculation of combinations of viruses. Am J Trop Med Hyg 22(3), 375-381.
27. N Bhamarapravati and S Yoksan (2000) Live attenuated tetravalent dengue vaccine. Vaccine 18(Suppl 2), 44-47.
28. N Bhamarapravati, S Yoksan, T Chayaniyayothin, et al. (1987) Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers. Bull World Health Organ 65 189-195.
29. N Bhamarapravati and S Yoksan (1997) Live attenuated tetravalent dengue vaccine. DJ Gubler, G Kuno (Eds) Dengue and dengue hemorrhagic fever New York: CAB International 367-377.
30. DW Vaughn, CH Hoke Jr, S Yoksan, et al. (1996) Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers. Vaccine 14 329-336.
31. N Kanesa-thasan, W Sun, G Kim-Ahn, et al. (2001) Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 19(23–24), 3179-3188.
32. N Bhamarapravati and S Yoksan (1989) Study of bivalent dengue vaccine in volunteers. Lancet 1 1077.
33. A Sabchareon, J Lang, P Chanthavanich, et al. (2004) Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr Infect Dis J 23(2), 99-109.
34. P Chanthavanich, C Luxemburger, C Sirivichayakul, et al. (2006) Immune response and occurrence of dengue infection in Thai children three to eight years after vaccination with live attenuated tetravalent dengue vaccine. Am J Trop Med Hyg 75(1), 26-28.
35. S Kitchener, M Nissen, P Nasveld, et al. (2006) Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine 24(9), 1238-1241.
36. V Sanchez, S Gimenez, B Tomlinson, et al. (2006) Innate and adaptive cellular immunity in flavivirus-naive human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3). Vaccine 24(23), 4914-4926.
37. R Edelman, CO Tacket, SS Wasserman, et al. (1994) A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans. J Infect Dis 170 1448-1455.
38. PA Mackowiak, SS Wasserman, CO Tacket, et al. (1994) Quantitative relationship between oral temperature and severity of illness following inoculation with candidate attenuated dengue virus vaccines. Clin Infect Dis 19 948-950.
39. W Sun, R Edelman, N Kanesa-Thasan, et al. (2003) Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg 69(6 Suppl), 24-31.
40. R Edelman, SS Wasserman, SA Bodison, et al. (2003) Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 69(6 Suppl), 48-60.
41. S Green, DW Vaughn, S Kalayanarooj, et al. (1999) Early immune activation in acute dengue illness is related to development of plasma leakage and disease severity. J Infect Dis 179(4), 755-762.
42. CJ Lai, BT Zhao, H Hori and M Bray (1991) Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus. Proc Natl Acad Sci U S A 88 5139-5143.
43. R Men, M Bray, D Clark, et al. (1996) Dengue type 4 virus mutants containing deletions in the 3′ noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. J Virol 70 3930-3937.
44. AP Durbin, SS Whitehead, J McArthur, et al. (2005) rDEN4 Delta 30, a Live Attenuated Dengue Virus Type 4 Vaccine Candidate, Is Safe, Immunogenic, and Highly Infectious in Healthy Adult Volunteers. J Infect Dis 191(5), 710-718.
45. W Chen, H Kawano, R Men, et al. (1995) Construction of intertypic chimeric dengue viruses exhibiting type 3 antigenicity and neurovirulence for mice. J Virol 69 5186-5190.
46. JE Blaney Jr, AP Durbin, BR Murphy and SS Whitehead (2006) Development of a live attenuated dengue virus vaccine using reverse genetics. Viral Immunol 19(1), 10-32.
47. L Zeng, B Falgout and L Markoff (1998) Identification of specific nucleotide sequences within the conserved 3′- SL in the dengue type 2 virus genome required for replication. J Virol 72(9), 7510-7522.
48. L Markoff, X Pang, HS Houng Hs, et al. (2002) Derivation and characterization of a dengue type 1 host range- restricted mutant virus that is attenuated and highly immunogenic in monkeys. J Virol 76(7), 3318-3328.
49. WH Bancroft, RM Scott, KH Eckels, et al. (1984) Dengue virus type 2 vaccine: reactogenicity and immunogenicity in soldiers. J Infect Dis 149(6), 1005-1010.
50. Kanesa-thasan N, Hernandez L, Lyons A, et al. A phase I study of the WRAIR tetravalent live attenuated dengue vaccine in flavivirus-immune adult volunteers. In: 5th Annual Conference on Vaccine Research; 2002 6–8 May 2002; Baltimore MD; 2002.
51. N Kanesa-Thasan, W Sun, GV Ludwig, et al. (2003) Atypical antibody responses in dengue vaccine recipients. Am J Trop Med Hyg 69(6 Suppl), 32-38.
52. DW Vaughn (2000) Invited commentary: Dengue lessons from Cuba. Am J Epidemiol 152(9), 800-803.
53. MG Guzman, GP Kouri, J Bravo, et al. (1990) Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study. Am J Trop Med Hyg 42 179-184.
54. DM Watts, KR Porter, P Putvatana, et al. (1999) Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic fever [see comments]. Lancet 354(9188), 1431-1434.
55. SB Halstead (1980) Immunological Parameters Of Togavirus Disease Syndromes. RW Schlesinger (Eds) The Toga-viruses: Biology Structure New York: Replication Academic Press 107-173.
56. EA Henchal and JR Putnak (1990) The dengue viruses. Clin Microbiol Rev 3(4), 376-396.
57. CM Rice, A Grakoui, R Galler and TJ Chambers (1989) Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation. New Biologist 1(3), 285-296.
58. TJ Chambers, A Nestorowicz, PW Mason and CM Rice (1999) Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J Virol 73(4), 3095-3101.
59. F Guirakhoo, R Weltzin, TJ Chambers, et al. (2000) Recombinant Chimeric Yellow Fever-Dengue Type 2 Virus Is Immunogenic and Protective in Nonhuman Primates. J Virol 74(12), 5477-5485.
60. J Arroyo, C Miller, J Catalan, et al. (2004) ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J Virol 78(22), 12497-12507.
61. CJ Lai and TP Monath (2003) Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis. Adv Virus Res 61 469-509.
62. F Guirakhoo, K Pugachev, J Arroyo, et al. (2002) Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology 298(1), 146-159.
63. F Guirakhoo, J Arroyo, KV Pugachev, et al. (2001) Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol 75(16), 7290-7304.
64. Monath TP, Myers GA, Beck RA, et al. Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: Infant mice provide an accurate surrogate for the test in monkeys. Biologicals 33(3):131–144.
65. F Guirakhoo, Z Zhang, G Myers, et al. (2004) A single amino acid substitution in the envelope protein of chimeric yellow Fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys. J Virol 78(18), 9998-10008.
66. F Guirakhoo, K Pugachev, Z Zhang, et al. (2004) Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol 78(9), 4761-4775.
67. BW Johnson, TV Chambers, MB Crabtree, et al. (2004) Analysis of the replication kinetics of the ChimeriVax-DEN 1, 2, 3, 4 tetravalent virus mixture in Aedes aegypti by real-time reverse transcriptase-polymerase chain reaction. Am J Trop Med Hyg 70(1), 89-97.
68. TP Monath, K McCarthy, P Bedford, et al. (2002) Clinical proof of principle for ChimeriVax: Recombinant live, attenuated vaccines against flavivirus infections. Vaccine 20(7–8), 1004-1018.
69. F Guirakhoo, S Kitchner, D Morrison, et al. (2006) Human Vaccines 2(2), 60-67.
70. RM Kinney, S Butrapet, GJ Chang, et al. (1997) Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53. Virology 230(2), 300-308.
71. RM Kinney and CY Huang (2001) Development of new vaccines against dengue fever and Japanese encephalitis. Intervirology 44(2–3), 176-197.
72. S Butrapet, CY Huang, DJ Pierro, et al. (2000) Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5′ noncoding region and nonstructural proteins 1 and 3. J Virol 74(7), 3011-3019.
73. CY Huang, S Butrapet, KR Tsuchiya, et al. (2003) Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. J Virol 77(21), 11436-11447.
74. CY Huang, S Butrapet, DJ Pierro, et al. (2000) Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. J Virol 74(7), 3020-3028.
75. S Butrapet, RM Kinney and CY Huang (2006) Determining genetic stabilities of chimeric dengue vaccine candidates based on dengue 2 PDK-53 virus by sequencing and quantitative TaqMAMA. J Virol Methods 131(1), 1-9.
76. TP Monath, N Kanesa-Thasan, F Guirakhoo, et al. (2005) Recombination and flavivirus vaccines: a commentary. Vaccine 23(23), 2956-2958.
77. H Aihara, T Takasaki, T Toyosaki-Maeda, et al. (2000) T-cell activation and induction of antibodies and memory T cells by immunization with inactivated Japanese encephalitis vaccine. Viral Immunol 13(2), 179-186.
78. CH Hoke Jr, A Nisalak, N Sangawhipa, et al. (1988) Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med 319 608-614.
79. SC Craig, PR Pittman, TE Lewis, et al. (1999) An accelerated schedule for tick-borne encephalitis vaccine: the American military experience in Bosnia. Am J Trop Med Hyg 61(6), 874-878.
80. R Putnak, DA Barvir, JM Burrous, et al. (1996) Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. J Infect Dis 174 1176-1184.
81. R Putnak, K Cassidy, N Conforti, et al. (1996) Immunogenic and protective response in mice immunized with a purified, inactivated, Dengue-2 virus vaccine prototype made in fetal rhesus lung cells. Am J Trop Med Hyg 55(5), 504-510.
82. J Robert Putnak, BA Coller, G Voss, et al. (2005) An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 23(35), 4442-4452.
83. R Putnak, A Fuller, L Vanderzanden, et al. (2003) Vaccination of rhesus macaques against dengue-2 virus with a plasmid dna vaccine encoding the viral prM and E genes. Am J Trop Med Hyg 68(4), 469-476.
84. MA Brinton, I Kurane, A Mathew, et al. (1998) Immune mediated and inherited defences against flaviviruses. Clin Diagn Virol 10(2–3), 129-139.
85. FA Rey, FX Heinz, C Mandl, et al. (1995) The envelope glycoprotein from tick-borne encephalitis virus at 2 angstrom resolution. Nature 375 291-298.
86. DW Trent, RM Kinney and CY Huang (1997) Recombinant dengue virus vaccines. DJ Gubler, G Kuno (Eds) Dengue and dengue hemorrhagic fever New York: CAB International
87. BAL Fonseca, K Khoshnood, RE Shope and PW Mason (1991) Flavivirus type-specific antigens produced from fusions of a portion of the E protein gene with the Escherichia coli TRPE gene. Am J Trop Med Hyg 44(5), 500-508.
88. AK Srivastava, JR Putnak, RL Warren and CH Hoke Jr (1995) Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection. Vaccine 13(13), 1251-1258.
89. Simmons M, Vaughn DW, Nisalak A, et al. Evaluation of recombinant viral envelope B domain protein antigens for the detection of dengue type specific antibodies. In: International Conference on Emerging Infectious Diseases; 1998 8–11 March 1998; Atlanta, GA; 1998.
90. C Delenda, MP Frenkiel and V Deubel (1994) Protective efficacy in mice of a secreted form of recombinant dengue-2 virus envelope protein produced in baculovirus infected insect cells. Arch Virol 139 197-207.
91. C Delenda, I Staropoli, MP Frenkiel, et al. (1994) Analysis of C-terminally truncated dengue 2 and dengue 3 virus envelope glycoproteins: Processing in insect cells and immunogenic properties in mice. J Gen Virol 75 1569-1578.
92. J Velzing, J Groen, MT Drouet, et al. (1999) Induction of protective immunity against Dengue virus type 2: comparison of candidate live attenuated and recombinant vaccines. Vaccine 17(11–12), 1312-1320.
93. H Bielefeldt-Ohmann, DW Beasley, DR Fitzpatrick and JG Aaskov (1997) Analysis of a recombinant dengue-2 virus-dengue-3 virus hybrid envelope protein expressed in a secretory baculovirus system. J Gen Virol 78(Pt 11), 2723-2733.
94. RJ Sugrue, J Fu, J Howe and YC Chan (1997) Expression of the dengue virus structural proteins in Pichia pastoris leads to the generation of virus-like particles. J Gen Virol 78(Pt 8), 1861-1866.
95. BT Zhao, G Prince, R Horswood, et al. (1987) Expression of dengue virus structural proteins and nonstructural protein NS1 by a recombinant vaccinia virus. J Virol 61 4019-4022.
96. V Deubel, RM Kinney, JJ Esposito, et al. (1988) Dengue 2 virus envelope protein expressed by a recombinant vaccinia virus fails to protect monkeys against dengue. J Gen Virol 69 1921-1929.
97. R Men, L Wyatt, I Tokimatsu, et al. (2000) Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge. Vaccine 18(27), 3113-3122.
98. JT Roehrig, AJ Johnson, AR Hunt, et al. (1992) Enhancement of the antibody response to flavivirus B-cell epitopes by using homologous or heterologous T-cell epitopes. J Virol 66 3385-3390.
99. Y Becker (1994) Dengue fever virus and Japanese encephalitis virus synthetic peptides, with motifs to fit HLA class I haplotypes prevalent in human populations in endemic regions, can be used for application to skin Langerhans cells to prime antiviral CD8(+) cytotoxic T cells (CTLs)—A novel approach to the protection of humans. Virus Genes 9 33-45.
100. JH Huang, JJ Wey, YC Sun, et al. (1999) Antibody responses to an immunodominant nonstructural 1 synthetic peptide in patients with dengue fever and dengue hemorrhagic fever. J Med Virol 57(1), 1-8.
101. G Garcia, DW Vaughn and RM Del Angel (1997) Recognition of synthetic oligopeptides from nonstructural proteins NS1 and NS3 of dengue-4 virus by sera from dengue virus-infected children. Am J Trop Med Hyg 56(4), 466-470.
102. FP Polack, PG Auwaerter, SH Lee, et al. (1999) Production of atypical measles in rhesus macaques: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion-inhibiting antibody. Nat Med 5(6), 629-634.
103. FP Polack, SJ Hoffman, G Crujeiras and DE Griffin (2003) A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles. Nat Med 9(9), 1209-1213.
104. MF Delgado and FP Polack (2004) Involvement of antibody, complement and cellular immunity in the pathogenesis of enhanced respiratory syncytial virus disease. Expert Rev Vaccines 3(6), 693-700.
105. RG Whalen (1996) DNA vaccines for emerging infectious diseases: what if. Emerging Infectious Diseases 2(3), 168-175.
106. T Kochel, SJ Wu, K Raviprakash, et al. (1997) Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice. Vaccine 15(5), 547-552.
107. KR Porter, TJ Kochel, SJ Wu, et al. (1998) Protective efficacy of a dengue 2 DNA vaccine in mice and the effect of CpG immuno-stimulatory motifs on antibody responses. Arch Virol 143(5), 997-1003.
108. K Raviprakash, TJ Kochel, D Ewing, et al. (2000) Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein. Vaccine 18(22), 2426-2434.
109. K Raviprakash, KR Porter, TJ Kochel, et al. (2000) Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques. J Gen Virol 81(Pt 7), 1659-1667.
110. K Raviprakash, D Ewing, M Simmons, et al. (2003) Needle-free Biojector injection of a dengue virus type 1 DNA vaccine with human immunostimulatory sequences and the GM-CSF gene increases immunogenicity and protection from virus challenge in Aotus monkeys. Virology 315(2), 345-352.
111. PJ Blair, TJ Kochel, K Raviprakash, et al. (2006) Evaluation of immunity and protective efficacy of a dengue-3 premembrane and envelope DNA vaccine in Aotus nancymae monkeys. Vaccine 24(9), 1427-1432.
112. SJ Wu, G Grouard-Vogel, W Sun, et al. (2000) Human skin Langerhans cells are targets of dengue virus infection. Nat Med 6(7), 816-820.
113. D Apt, K Raviprakash, A Brinkman, et al. (2006) Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen. Vaccine 24(3), 335-344.
114. K Raviprakash, D Apt, A Brinkman, et al. (2006) A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques. Virology 353(1), 166-173.
115. DM Klinman, M Takeno, M Ichino, et al. (1997) DNA vaccines: safety and efficacy issues. Springer Semin Immunopathol 19(2), 245-256.
116. WW Nichols, BJ Ledwith, SV Manam and PJ Troilo (1995) Potential DNA vaccine integration into host cell genome. Ann N Y Acad Sci 772 30-39.
117. T Martin, SE Parker, R Hedstrom, et al. (1999) Plasmid DNA malaria vaccine: the potential for genomic integration after intramuscular injection. Hum Gene Ther 10(5), 759-768.
118. SE Parker, F Borellini, ML Wenk, et al. (1999) Plasmid DNA malaria vaccine: tissue distribution and safety studies in mice and rabbits. Hum Gene Ther 10(5), 741-758.
119. G Mor, M Singla, AD Steinberg, et al. (1997) Do DNA vaccines induce autoimmune disease. Hum Gene Ther 8(3), 293-300.
120. GJ Prud’homme, BR Lawson, Y Chang and AN Theofilopoulos (2001) Immunotherapeutic gene transfer into muscle. Trends Immunol 22(3), 149-155.
121. N Karin (2000) Gene therapy for T cell-mediated autoimmunity: teaching the immune system how to restrain its own harmful activities by targeted DNA vaccines. Isr Med Assoc J 2(Suppl), 63-68.